2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Genitourinary
2
CNS
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
36
Neoplasms
8
Lung Neoplasms
7
Neoplasm Metastasis
4
Neoplasms by Site
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sexual Dysfunction, Physiological
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
alectinib
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts